Back to search

Peptide record

TPDB92319

[A18K]OCN-3N Antibacterial Anticancer Antifungal Toxicity standard
19 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92319
[A18K]OCN-3N
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0 dbACP
standard
No
A 19-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from Peptipedia, CancerPPD 2.0, and dbACP, with an available 3D structural model.
C-terminal: Amidation
Sequence
GIFDVLKNLAKGVITSLKS-NH2
Physicochemical Analysis
C92H159N23O26
RCEQHMPWY
LK
2003.41
10.32
3
1
9
+2
1.58
0.611
138.42
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
4
Residue Composition
number
1
A
0
R
1
N
1
D
0
C
0
E
0
Q
2
G
0
H
2
I
3
L
3
K
0
M
1
F
0
P
2
S
1
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 1 R: 0 N: 1 D: 1 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 2 L: 3 K: 3 M: 0 F: 1 P: 0 S: 2 T: 1 W: 0 Y: 0 V: 2
Chemical Descriptors
19
C92H159N23O26
2003.41
10.32
+2
1.58
0.611
Amidation
L
Linear
Free
Host Defense
Synthetic Derivative of ocellatin-3N
Evidence Records 3 records
Evidence 1 Activity

Activity

LC50
LC50 = 30 ± 1 µM
Anticancer
30

Target

Lung Cancer
A-549
Lung

Assay & Model

CellTiter-Glo assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LC50
LC50 = 69 ± 18 µM
Anticancer
69

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

CellTiter-Glo assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 3 Activity

Activity

LC50
LC50 = 59 ± 4 µM
Anticancer
59

Target

Colorectal Cancer
HT-29
Colon

Assay & Model

CellTiter-Glo assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022